



ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 13355

Title: Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma

Reviewer code: 02445141

Science editor: Jing Yu

Date sent for review: 2014-08-20 15:40

Date reviewed: 2014-09-18 09:35

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The paper by Zhang et al. demonstrated the significance of MYC and BCL-2 co-expression on the prognosis of primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL). Multivariate analysis revealed that MYC and BCL-2 double positive phenotype was the independent factor for poorer response to chemotherapy and poorer prognosis. The presentation of the data was clear and experiments were performed carefully. Although the functional aspects of this phenotype were not investigated in the study, the precise identification of MYC/BCL-2 expression in PGI-DLBCL is quite important for clinical settings. Furthermore, the elucidation of the regulatory mechanisms of resistance to chemotherapy as well as patients prognosis would be of wider interest, particularly from the aspects of future therapeutic strategies. General comments: 1. What was the difference in significance of examining MYC/BCL-2 expression in PGI-DLBCL from the examination in DLBCL? In DLBCL, Johnson et al. (J Clin Oncol, 2012) had published the excellent study. 2. Discussion section would be too long. Authors could reduce the repetition. Minor comments: 1. Materials and Methods, Patients: Authors would better demonstrate the expression status of CD20, CD10 and possibly CD5 in lymphoma cells of PGI-DLBCL patients. Also the chromosomal abnormality data would have significance. 2. Materials and Methods, Patients: Normal control samples were taken from lymphoid tissue. Are they lymph nodes? Tonsils? Lymph follicles in the gastric mucosa? 3. Materials and Methods, Immunohistochemistry: Please indicate the reason



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

why the authors selected 30% as the standard for positive.